相关实验视频

Updated: Jul 2, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

下一代HER2向抗体-药物结合物在乳腺癌中

Brittney S Zimmerman^1,2, Francisco J Esteva^1,2

¹Northwell, New Hyde Park, NY 11042, USA.

|February 24, 2024

概括

新的抗体药物合物 (ADC) 为乳腺癌提供精确的HER2向治疗. 这些先进的治疗方法旨在改善HER2-阳性和HER2-低疾病患者的治疗结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

人类表皮生长因子受体2 (HER2) 在20%的乳腺癌中过度表达,与更差的预后相关.
传统的治疗方法包括化疗和针对HER2的单克隆抗体 (例如,特拉斯图祖马布,珀图祖马布).

研究的目的:

审查乳腺癌治疗中针对HER2的抗体-药物合物 (ADCs) 的现状.
讨论新兴的HER2向的研究ADC及其潜在影响.

主要方法:

对HER2向性ADC的当前文献和临床试验数据的审查.
对特斯图苏巴姆艾姆坦辛 (T-DM1) 和特斯图苏巴姆德鲁克斯坦干 (T-DXd) 等ADC的结构,机制和临床应用的分析.

主要成果:

针对HER2的ADCs,如T-DM1和T-DXd,代表了一种新的治疗类别,将单克隆抗体与细胞毒性有效载荷相结合.
目前正在进行的研究重点是新的组合和顺序方法,以克服对现有的ADCs的耐药性.
新的ADC正在开发中,以提高HER2向治疗的精度和降低毒性.

结论:

针对HER2的ADC正在彻底改变乳腺癌的治疗方法,提供更高的精度和潜在的更好的结果.
临床试验对于优化剂量,了解耐药性和确定从这些疗法中受益最多的患者子组来说至关重要.
这些先进的ADC对HER2阳性和HER2-低乳腺癌患者具有显著的前景.

关键词:

在HER2中,HER2是HER2.抗体药物联合体抗体药物联合体乳腺新生瘤的发生.药物耐药性耐药性药物耐药性有针对性的治疗.特拉斯图祖马布可以脱.这就是trastuzumab-DM1的作用.

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...